Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

November 21, 2024

Article

Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

November 18, 2024

Article

Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.

Dr Lin on the Safety of T-DXd for HER2+ Breast Cancer With/Without Brain Metastases

November 15, 2024

Video

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

Dr DeAngelo on Non-Chemotherapy Treatment Options in CLL

November 15, 2024

Video

Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.

Dr DeAngelo on the Integration of JAK Inhibitors in Myelofibrosis Management

November 11, 2024

Video

Daniel DeAngelo, MD, discusses the integration of JAK inhibitors into clinical practice for patients with myelofibrosis.

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

November 08, 2024

Article

The biomarker analysis of patients enrolled on part B of the CheckMate 914 trial explored the effects of PD-L1 and KIM-1 expression.

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

November 01, 2024

Article

David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been named to the National Academy of Medicine.

Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives

October 28, 2024

Article

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

October 28, 2024

Article

Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma

October 26, 2024

Article

David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.

Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row

October 25, 2024

Article

U.S. News & World Report has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation.

INCA033989 May Address Need for Disease-Modifying Therapies in Myelofibrosis

October 25, 2024

Article

Daniel J. DeAngelo MD, PhD, discusses the potential role for INCA033989 as a disease-modifying therapy in CALR type 1–mutated myelofibrosis.

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

October 21, 2024

Article

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases

October 16, 2024

Article

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Dr Lin on the Importance of the DESTINY-Breast12 Trial for T-DXd Use in HER2+ Breast Cancer With Brain Metastases

October 16, 2024

Video

Nancy U. Lin, MD, discusses the importance of the DESTINY-Breast12 trial of T-DXd in patients with HER2+ breast cancer with vs without brain metastases.

Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets

October 14, 2024

Article

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

October 09, 2024

Article

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Cigall Kadoch, PhD, Wins Prestigious Blavatnik National Award

October 07, 2024

Article

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

October 04, 2024

Article

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

Dr Machaalani on the Incidence of ERBB2 Amplifications Across Race, Sex, and Cancer Type

October 04, 2024

Video

Marc Machaalani, MD, discusses an investigation into the distribution of ERBB2 amplifications across sex, race, and varying cancer types.